Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.
3.

Poorer physical health-related quality of life among Aboriginals and injection drug users treated with highly active antiretroviral therapy.

Martin LJ, Houston S, Yasui Y, Wild TC, Saunders LD.

Can J Public Health. 2012 Nov 8;104(1):e33-8.

PMID:
23618106
4.

Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study.

Larsen MV, Omland LH, Gerstoft J, Larsen CS, Jensen J, Obel N, Kronborg G.

Addiction. 2010 Mar;105(3):529-35. doi: 10.1111/j.1360-0443.2009.02827.x.

PMID:
20402997
5.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
6.

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP.

J Infect Dis. 2009 Apr 1;199(7):991-8. doi: 10.1086/597124.

PMID:
19220139
7.

Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.

Larsen MV, Omland LH, Gerstoft J, Røge BT, Larsen CS, Pedersen G, Obel N, Kronborg G.

Scand J Infect Dis. 2010 Dec;42(11-12):917-23. doi: 10.3109/00365548.2010.511258. Epub 2010 Sep 15.

PMID:
20840000
8.
9.

Antiretroviral treatment outcomes among foreign-born and Aboriginal peoples living with HIV/AIDS in northern Alberta.

Lefebvre ME, Hughes CA, Yasui Y, Saunders LD, Houston S.

Can J Public Health. 2014 Jul 11;105(4):e251-7. Erratum in: Can J Public Health. 2015 Jan-Feb;106(2):e85.

PMID:
25166126
10.

Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.

Yang CH, Huang YF, Hsiao CF, Yeh YL, Liou HR, Hung CC, Yang SY.

HIV Med. 2008 Aug;9(7):535-43. doi: 10.1111/j.1468-1293.2008.00600.x. Epub 2008 Jun 28.

11.
12.

Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study.

Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulougou B, Kaboré I, Sanou MJ, Greenwell F, Soudré R, Sondo B.

AIDS Care. 2012;24(4):478-90. doi: 10.1080/09540121.2011.630353. Epub 2011 Dec 7.

PMID:
22148973
14.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators.

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
15.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.

16.

The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.

Ferreros I, Lumbreras B, Hurtado I, Pérez-Hoyos S, Hernández-Aguado I.

Addiction. 2008 Apr;103(4):651-9. doi: 10.1111/j.1360-0443.2008.02135.x.

PMID:
18339110
17.

The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study.

Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT; HOPS (HIV Outpatient Study) Investigators.

Ann Intern Med. 2009 Jul 21;151(2):73-84.

PMID:
19620160
18.

Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.

Rodríguez-Arenas MA, Jarrín I, del Amo J, Iribarren JA, Moreno S, Viciana P, Peña A, Sirvent JL, Vidal F, Lacruz J, Gutierrez F, Oteo JA, Asencio R, Castilla J, Hoyos SP; CoRIS-MD.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):715-23.

PMID:
16910826
19.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
20.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199

Supplemental Content

Support Center